AXL and cancer: reported that human BRAF‐mutant melanoma cells display single‐cell transcriptional heterogeneity, which results in transient upregulation of several resistance genes in a small portion of cells, such as AXL, WNT5, EGFR, JUN, and PDGFRB, leading to development of drug resistance and survival of cancer cells from vemurafenib therapy.